News articles about Puma Biotechnology (NASDAQ:PBYI) have trended somewhat positive on Friday, according to Accern Sentiment Analysis. The research firm identifies positive and negative press coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Puma Biotechnology earned a news impact score of 0.10 on Accern’s scale. Accern also gave press coverage about the biopharmaceutical company an impact score of 46.2767282545126 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
These are some of the news stories that may have effected Accern Sentiment’s rankings:
Puma Biotechnology (PBYI) opened at $88.25 on Friday. The firm has a market cap of $3,310.00, a price-to-earnings ratio of -10.78 and a beta of 0.72. Puma Biotechnology has a 1-year low of $28.35 and a 1-year high of $136.90.
Puma Biotechnology (NASDAQ:PBYI) last posted its earnings results on Thursday, November 9th. The biopharmaceutical company reported ($2.07) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($2.50) by $0.43. The business had revenue of $6.10 million for the quarter, compared to analyst estimates of $3.78 million. During the same quarter in the previous year, the firm posted ($1.11) EPS. research analysts forecast that Puma Biotechnology will post -8.17 earnings per share for the current year.
A number of brokerages have weighed in on PBYI. Royal Bank of Canada decreased their price target on shares of Puma Biotechnology from $108.00 to $92.00 and set a “sector perform” rating on the stock in a report on Friday, November 10th. They noted that the move was a valuation call. Credit Suisse Group reiterated an “outperform” rating and issued a $136.00 price target on shares of Puma Biotechnology in a report on Wednesday, September 27th. JPMorgan Chase & Co. reiterated a “buy” rating and issued a $131.00 price target on shares of Puma Biotechnology in a report on Wednesday, October 4th. ValuEngine lowered shares of Puma Biotechnology from a “hold” rating to a “sell” rating in a report on Wednesday, January 3rd. Finally, Barclays reiterated a “buy” rating and issued a $122.00 price target (up previously from $103.00) on shares of Puma Biotechnology in a report on Friday, November 10th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and nine have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $130.67.
In related news, insider Charles R. Eyler sold 1,322 shares of Puma Biotechnology stock in a transaction on Friday, December 1st. The shares were sold at an average price of $105.46, for a total transaction of $139,418.12. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 21.10% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This story was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this story on another domain, it was illegally stolen and republished in violation of United States & international trademark & copyright laws. The original version of this story can be accessed at https://www.dispatchtribunal.com/2018/01/19/somewhat-positive-news-coverage-somewhat-unlikely-to-impact-puma-biotechnology-pbyi-stock-price.html.
Puma Biotechnology Company Profile
Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357.
Receive News & Ratings for Puma Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.